Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.
This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.